News

miRagen Therapeutics at Keystone Symposia

Friday, February 11, 2011

miRagen Therapeutics, Inc announced that its Co-Founder/Chief Scientific Advisor, Eric N. Olson, Ph.D., and scientific Co-Founder/Director of Biology, Eva van Rooij, Ph.D., are serving as Scientific Organizers as well as presenters at the first Keystone Symposia on Molecular and Cellular Biology conference focused on MicroRNAs and Human Disease. The conference will take place February 11-16, 2011, in Banff, Alberta, Canada.   

Corgenix Medical will highlight AspirinWorks

Wednesday, February 09, 2011

During the conference Pri-Med South 2011, Corgenix Medical Corp. (Denver) will highlight its AspirinWorks® Test for aspirin effect in booth No. 902 at the Broward County Convention Center if Fort Lauderdale, FL.   AspirinWorks is a simple, non-invasive lab test performed on a urine specimen. It is the only FDA-cleared test that helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring the urine levels of 11-dehydro thromboxane B2 (11-dhTxB2), a metabolite of thromboxane, the target of aspirin therapy. Individuals with high levels of 11-dhTxB2 are at increased risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.  

OnBioVC Trend Analysis

Tuesday, February 08, 2011

4Q10 & 2010 TREND ANALYSIS
Bioscience VC, M&A and IPO Overview 

Lung Cancer Prevention Grant Program

Monday, February 07, 2011

The University of Colorado Denver Office of the Vice Chancellor for Research  

Sharklet on CBS Sunday Morning

Sunday, February 06, 2011

How Shark Skin May Help Save Lives
David Pogue Looks at How a Material That Prevents Bacterial Growth Was Inspired by the Most Feared Predator of the Sea 

Colorado’s Bioscience Discovery Evaluation Grant Program Creates 598 New Jobs in the State, with Payroll Exceeding $44 million

Friday, February 04, 2011

Denver - The Colorado BioScience Association (CBSA) and The Colorado Office of Economic Development and International Trade (OEDIT) have jointly released results of the Bioscience Discovery Evaluation Grant Program (BDEGP) at the CBSA's Third Annual "Bioscience Day at the Capitol" event. The announcement is made by Holli Baumunk, CBSA President & CEO, who says the BDEGP has more than met expectations since its inception in 2006, providing the state a significant return on investment. 

AdvaMed Medical Device Repeal Bill

Thursday, February 03, 2011

AdvaMed, the industry group representing medical device manufactures, largely supported the reform law but held reservations about the law's medical device tax. On Thursday, the group endorsed the bill repealing the tax, but it reiterated its support for the reform effort.

"While AdvaMed supports repeal of the excise tax, it remains committed to the central elements of health reform that are consistent with our long-held principles, including expanded coverage, reform of the payment system to encourage quality and efficiency, and a new emphasis on health promotion and disease prevention," AdvaMed President and CEO Stephen Ubl said in a statement. "As other proposed changes to the bill are considered by Congress, we will evaluate them in the light of these principles and their impact on patients and medical innovation.” 

InDevr signs global distributors

Wednesday, February 02, 2011

BOULDER, Colo. – February 1, 2011 – InDevR, one the West’s fastest growing biotechnology companies, today announced it has signed six agreements with leading life science instrument distributors for US and international territories to market the company’s ViroCyt™ 2100 Virus Counter®.  

BioScience Day at the Capitol Speakers

Wednesday, February 02, 2011

 

BioScience Day at the Capitol

Wednesday, February 02, 2011

Colorado's Bioscience Discovery Evaluation Grant Program Creates 598 New Jobs in the State, with Payroll Exceeding $44 million